Ascendia Pharmaceuticals, Inc., a North Brunswick, NJ-based specialty contract development and manufacturing organization (CDMO) dedicated to developing and manufacturing enhanced formulations for pre-clinical, clinical stage drug candidates, and marketed drug products, received an investment from Signet Healthcare Partners.
The amount of the deal was not disclosed.
The company intends to use the funds for facility expansion.
Founded in 2012 and led by CEO Dr. Jim J. Huang, Ascendia Pharmaceuticals is a specialty CDMO dedicated to developing and manufacturing enhanced formulations for pre-clinical and clinical stage drug candidates and marketed drug products. The company specializes in improving the solubility and bioavailability of poorly water-soluble drugs using its suite of nanotechnology platforms. Ascendia formulates products for injectable, oral, and topical routes of administration. The company has three technology platforms – EmulSol® for producing nano-emulsions, AmorSol® for creating amorphous solid dispersions, and NanoSol® for formulating nano-particles.
FinSMEs
19/04/2021